Ikena Oncology (IKNA) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on innovative therapies for autoimmune, immunological, and inflammatory (I&I) diseases.

• Lead asset IMG-007 is a non-depleting anti-OX40 monoclonal antibody, initially targeting atopic dermatitis (AD) with potential for other I&I indications.

• IMG-007 demonstrated marked clinical activity and durable inhibition of inflammatory markers in early trials, with a favorable safety profile.

• The company completed a merger with Ikena Oncology, Inc., resulting in a new entity, ImageneBio, Inc., with a focus on IMG-007.

• IMG-007 and its technology are exclusively licensed from Hutchmed, with manufacturing support from Wuxi Biologics.

Financial performance and metrics

• Net loss for the six months ended June 30, 2025: $13.7 million; for the year ended December 31, 2024: $36.6 million.

• Accumulated deficit as of June 30, 2025: $197.5 million.

• Cash and cash equivalents as of June 30, 2025: $6.0 million; post-merger, received $95.2 million in cash and $75.0 million from PIPE financing.

• Revenue is derived from license payments; no product sales to date.

• Operating losses are expected to continue as the company advances clinical development.

Use of proceeds and capital allocation

• Proceeds from the PIPE financing ($75.0 million) are allocated to advance the clinical pipeline, business development, working capital, and general corporate purposes.

• The company will not receive proceeds from the resale of shares by selling stockholders.

• Additional funding will be required to complete development and commercialization of IMG-007 and future candidates.